Drugs / GLY-200
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06259981 | May → Oct 2024 | obesity disorder | Glyscend, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05478525 | Aug 2022 → Mar 2023 | type 2 diabetes mellitus | Glyscend, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-07-27 | Glyscend, Inc. | Results Glyscend Therapeutics Announces Publication of GLY-200 First-in-Human Data and Availability of Phase 2a Clinical Results glyscend.com ↗
The data published demonstrate that GLY-200, the company’s lead clinical candidate, mimics the biomarker signature seen with metabolic surgery and appeared to be safe and generally well-tolerated. |
| 2023-05-31 | Glyscend, Inc. | Results Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity glyscend.com ↗
Data across completed Phase 1 and Phase 2a clinical trials demonstrated that the novel mechanism of GLY-200 offers significant and clinically relevant reductions in postprandial glucose and body weight and support its advancement into a Phase 2b clinical trial. |
| 2022-09-20 | Glyscend, Inc. | Results Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment glyscend.com ↗
B oston, MA (September 20, 2022) – Glyscend Therapeutics , a clinical-stage biotechnology company, today reported additional biomarker results from their Phase 1 study of GLY-200, a proprietary orally administered, gut-restricted therapeutic for the treatment of type 2 diabetes (T2D). |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLY-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05478525 ↗ |
| Modality | Other / unclassified | “GLY-200 is an investigational oral polymeric drug” PMID 40767317 ↗ Aug 2025 |
| Route | Oral | “investigational oral polymeric drug” PMID 40767317 ↗ Aug 2025 |